CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 1, 2009, Pages 186-192

  Yamashita, Makoto ^a   Tomozawa, Takanori ^a   Kakuta, Masayo ^a   Tokumitsu, Akane ^a   Nasu, Hatsumi ^a   Kubo, Shuku ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDO 4 GUANIDINO 6 (2 HYDROXY 1 METHOXY 3 OCTANOYLOXYPROPYL) 5,6 DIHYDRO 4H PYRAN 2 CARBOXYLIC ACID; ANTIVIRUS AGENT; CS 8958; OSELTAMIVIR; R 125489; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS INHIBITION; VIRUS RESISTANCE; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; HELA CELLS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MICE; NEURAMINIDASE; PRODRUGS; ZANAMIVIR;

EID: 59749091876     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00333-08     Document Type: Article

References (19)

1. Bantia, S., A. A. Ghate, S. L. Ananth, Y. S. Babu, G. M. Air, and G. M. Walsh. 1998. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140. Antimicrob. Agents Chemother. 42:801-807.
2. Bright, R. A., D. K. Shay, B. Shu, N. J. Cox, and A. I. Klimov. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894.
3. Bright, R. A., D. Shay, J. Bresee, A. Klimov, N. Cox, and J. Ortiz. 2006. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season. MMWR Morb. Mortal. Wkly. Rep. 55:44-46.
4. Fiore, A. E., D. K. Shay, P. Haber, J. K. Iskander, T. M. Uyeki, G. Mootrey, J. S. Bresee, and N. J. Cox. 2007. Prevention and control of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 56:1-54.
5. Gubareva, L. V. 2004. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103:199-203.
6. Hatakeyama, S., N. Sugaya, M. Ito, M. Yamazaki, M. Ichikawa, K. Kimura, M. Kiso, H. Shimizu, C. Kawakami, K. Koike, K. Mitamura, and Y. Kawaoka. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-1442.
7. Hay, A. J., A. J. Wolstenholme, J. J. Skehel, and M. H. Smith. 1985. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4:3021-3024.
8. Hayden, F. G. 2006. Antiviral resistance in influenza viruses - implications for management and pandemic response. N. Engl. J. Med. 354:785-788.
9. Honda, T., T. Masuda, S. Yoshida, M. Arai, Y. Kobayashi, and M. Yamashita. 2002. Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives. Bioorg. Med. Chem. Lett. 12:1921-1924.
10. Honda, T., T. Masuda, S. Yoshida, M. Arai, S. Kaneko, and M. Yamashita. 2002. Synthesis and anti-influenza virus activity of 7 derivatives related to zanamivir. Bioorg. Med. Chem. Lett. 12:1925-1928.
11. Kiso, M., K. Mitamura, Y. Sakai-Tagawa, K. Shiraishi, C. Kawakami, K. Kimura, F. G. Hayden, N. Sugaya, and Y. Kawaoka. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765.
12. Lackenby, A., O. Hungnes, S. G. Dudman, A. Meijer, W. J. Paget, A. J. Hay, and M. C. Zambon. 2008. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 13:1-2.
13. Le, Q. M., M. Kiso, K. Someya, Y. T. Sakai, T. H. Nguyen, K. H. L. Nguyen, N. D. Pham, H. H. Ngyen, S. Yamada, Y. Muramoto, T. Horimoto, A. Takada, H. Goto, T. Suzuki, Y. Suzuki, and Y. Kawaoka. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature (London) 437:1108.
14. Macdonald, S. J., R. Cameron, D. A. Demaine, R. J. Fenton, G. Foster, D. Gower, J. N. Hamblin, S. Hamilton, G. J. Hart, A. P. Hill, G. G. Inglis, B. Jin, H. T. Jones, D. B. McConnell, J. McKimm-Breschkin, G. Mills, V. Nguyen, I. J. Owens, N. Parry, S. E. Shanahan, D. Smith, K. G. Watson, W. Y. Wu, and S. P. Tucker. 2005. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J. Med. Chem. 48:2964-2971.
15. Macdonald, S. J., K. G. Watson, R. Cameron, D. K. Chalmers, D. A. Demaine, R. J. Fenton, D. Gower, J. N. Hamblin, S. Hamilton, G. J. Hart, G. G. Inglis, B. Jin, H. T. Jones, D. B. McConnell, A. M. Mason, V. Nguyen, I. J. Owens, N. Parry, P. A. Reece, S. E. Shanahan, D. Smith, W. Y. Wu, and S. P. Tucker. 2004. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob. Agents Chemother. 48:4542-4549.
16. Nakai, N., N. Yamamura, M. Hoshi, M. Oitate, N. Kobayashi, T. Hirota, M. Kazui, and K. Kawai. 2003. R-118958, a unique anti-influenza agent: pharmacokinetics and metabolism after intranasal/intratracheal administration to rats and mice. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-1833.
17. Ryan, D. M., J. Ticehurst, M. H. Dempsey, and C. R. Penn. 1994. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4- dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob. Agents Chemother. 38:2270-2275.
18. Wright, P. F., and R. G. Webster. 2001. Orthomyxoviruses, p. 1534-1579. In D. M. Knipe, P. M. Howley, D. E. Griffin, et al. (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
19. Yamashita, M. 2004. R-118958, a unique anti-influenza agent showing high efficacy for both prophylaxis and treatment after a single administration: from the in vitro stage to phase I study. Int. Congr. Ser. 1263:38-42.